首页> 美国卫生研究院文献>Communications Biology >Exosome loaded immunomodulatory biomaterials alleviate local immune response in immunocompetent diabetic mice post islet xenotransplantation
【2h】

Exosome loaded immunomodulatory biomaterials alleviate local immune response in immunocompetent diabetic mice post islet xenotransplantation

机译:外渗的免疫调节生物材料缓解免疫活性糖尿病小鼠的局部免疫应答后胰岛外膜持续

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

a Non-fasting blood glucose levels in C57/BL6 STZ-induced diabetic mice (n = 5 mice) shows that transplantation of 1500 IEQ rat islets within AlgXO provided euglycemia in diabetic mice for >170 days, whereas the CTRL microcapsules failed in <1 month. To further confirm that the glycemic correction is merely due to transplants and not pancreatic regeneration in STZ-induced diabetic mice, we washed the i.p. cavity of mice and removed the explants after 105 days of transplantation (n = 2 mice). Within 18 h of graft removal, mice blood glucose elevated and remained hyperglycemic for the rest of their lifetime (dashed green line). Separate i.p. transplantation of islets within CTRL microcapsules and XOs provided normoglycemia for ~70 days (black line, n = 4 mice). b We further tested the efficacy of AlgXO transplants in response to oral glucose tolerance test (OGTT). One month after transplantation, similar to STZ mice (n = 6 mice), CTRL microcapsules failed to regulate the glucose levels (n = 4 mice), whereas AlgXO transplants successfully reversed hyperglycemia event induced by glucose challenge (n = 6 mice), with similar trend as non-diabetic controls. c The average time to reach normoglycemia after an OGTT for non-diabetic mice was 65 ± 27 min and for mice with AlgXO transplants was 103 ± 32 min (n = 6 mice). d After 1 month, both CTRL and AlgXO (from 1500 IEQ group) transplants were removed through washing the i.p. cavity. Next, microcapsules were analyzed for the immune infiltration (also known as pericapsular cell growth) with laser-scanning confocal microscopy. Some cells were CD11b+ and some of the CD11b+ cells were expressing MHCII biomarker. All the collected CTRL microcapsules were found to have pericapsular cells attached to the surface, while the percentage of AlgXO transplants with pericapsular growth was 9.4% ± 3.6%, which was significantly lower than CTRL transplants (p < 0.0001). Scale bars are 200 μm for the dark field and 100 μm for the florescent channels. e The pericapsular cytokine and chemokines present released in the pericapsular area of implants. Results are mean ± SD, and statistical significance is calculated through unpaired t-test with Welch’s correction. 1: STZ injection; 2: Diabetes induction period; 3: Transplantation; 4: Graft removal.
机译:C57 / BL6 STZ诱导的糖尿病小鼠(n = 5只小鼠)的非空腹血糖水平表明,在Algxo内的1500只Ieq大鼠胰岛的移植在糖尿病小鼠中提供了糖尿病小鼠的eGlycemia,而Ctrl微胶囊在<1中失效月。为了进一步证实血糖矫正仅仅是由于移植物而不是STZ诱导的糖尿病小鼠的胰腺再生,我们洗涤了I.P.小鼠的腔体并在移植105天后除去外植体(n = 2只小鼠)。在移植物移除的18小时内,小鼠血糖升高,其余的寿命(虚线绿线)仍然保持高血糖。分开i.p.在CTRL微胶囊和XOS内移植胰岛,XOS提供〜70天的常规血糖(黑线,N = 4只小鼠)。 B我们进一步测试了藻类移植响应口腔葡萄糖耐量试验(OGTT)的疗效。移植后一个月,类似于STZ小鼠(n = 6只小鼠),CTRL微胶囊未能调节葡萄糖水平(n = 4只小鼠),而藻类移植成功逆转葡萄糖攻击(n = 6只小鼠)诱导的高血糖事件(n = 6只小鼠)。类似趋势作为非糖尿病对照。 C对于非糖尿病小鼠的OGTT后,达到正常血糖的平均时间为65±27分钟,对于藻类移植的小鼠为103±32分钟(n = 6只小鼠)。 d 1个月后,通过洗涤i.p,去除Ctrl和Algxo(来自1500个IEQ组)移植物。腔。接下来,通过激光扫描共聚焦显微镜分析用于免疫浸润(也称为腓骨增长)的微胶囊。一些细胞是CD11b +,并且一些CD11b +细胞表达MHCII生物标志物。发现所有收集的CTRL微胶囊都有近覆盖物的细胞,而藻类移植的百分比具有9.4%±3.6%,显着低于CTRL移植(P <0.0001)。暗场为200μm为200μm,荧光通道为100μm。 e在植入物的繁殖区域释放的腓骨细胞因子和趋化因子。结果是平均值±SD,统计显着性通过与韦尔奇的矫正无配对T检验来计算。 1:STZ注射; 2:糖尿病诱导期; 3:移植; 4:移植移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号